The Federal Circuit has issued a precedential decision reversing a lower court’s decision that certain claims of Novartis’s ...

Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking drugmaker MSN Pharmaceuticals ...

Entresto’s importance to Novartis is illustrated in the company’s most recent quarterly report, which revealed that the drug generated $5.6 billion in the first three quarters of 2024 ...

The US Court of Appeals for the Federal Circuit reversed a district court’s ruling of invalidity for lack of written description, finding that ...

The launch of a generic version of Novartis's (NYSE:NVS) blockbuster cardiac drug Entresto has reportedly been temporarily blocked by a federal appeals court as it considers the drugmaker's ...

Basel, January 13, 2025 – Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto ® (sacubitril/valsartan ...

WASHINGTON -A federal appeals court temporarily paused drugmaker MSN Pharmaceuticals' launch of a generic version of Novartis' blockbuster heart-failure drug Entresto late on Wednesday.

(RTTNews) - Swiss drug major Novartis (NVS) Monday announced that the US Court of Appeals for the Federal Circuit or CAFC has decided to upheld the validity of the Entresto (sacubitril/valsartan ...

Novartis (NVS) announced it “is pleased with the decision by the US Court of Appeals for the Federal Circuit, CAFC, that affirms the validity of the Entresto combination patent. We will work to ...